These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30605833)

  • 1. Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents.
    Li Z; Chen Y; Zhou Z; Deng L; Xu Y; Hu L; Liu B; Zhang L
    Eur J Med Chem; 2019 Feb; 164():352-365. PubMed ID: 30605833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
    Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
    Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.
    Li Z; Hu L; Wang X; Zhou Z; Deng L; Xu Y; Zhang L
    Bioorg Chem; 2019 Nov; 92():103254. PubMed ID: 31518760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold.
    Zhou Z; Cai Z; Zhang C; Yang B; Chen L; He Y; Zhang L; Li Z
    Bioorg Med Chem; 2022 Feb; 56():116615. PubMed ID: 35051813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
    Li Z; Qiu Q; Xu X; Wang X; Jiao L; Su X; Pan M; Huang W; Qian H
    Eur J Med Chem; 2016 May; 113():246-57. PubMed ID: 26945112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel FFA1 agonist, CPU025, improves glucose-lipid metabolism and alleviates fatty liver in obese-diabetic (ob/ob) mice.
    Li Z; Liu C; Zhou Z; Hu L; Deng L; Ren Q; Qian H
    Pharmacol Res; 2020 Mar; 153():104679. PubMed ID: 32014571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold.
    Li Z; Xu X; Hou J; Wang S; Jiang H; Zhang L
    Bioorg Chem; 2018 Apr; 77():429-435. PubMed ID: 29433092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosis.
    Li Z; Zhou Z; Hu L; Deng L; Ren Q; Zhang L
    Pharmacol Res; 2020 Sep; 159():105035. PubMed ID: 32562818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry.
    Li Z; Yang J; Wang X; Li H; Liu C; Wang N; Huang W; Qian H
    Bioorg Med Chem; 2016 Nov; 24(21):5449-5454. PubMed ID: 27624524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes.
    Wang B; Cai Z; Yao H; Jiao S; Chen S; Yang Z; Huang W; Ren Q; Cao Z; Chen Y; Zhang L; Li Z
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114883. PubMed ID: 36343410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold.
    Li Z; Ren Q; Wang X; Zhou Z; Hu L; Deng L; Guan L; Qiu Q
    Bioorg Chem; 2019 Nov; 92():103209. PubMed ID: 31487621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPAR dual agonists: are they opening Pandora's Box?
    Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
    Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus.
    Defossa E; Wagner M
    Bioorg Med Chem Lett; 2014 Jul; 24(14):2991-3000. PubMed ID: 24881568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triterpenoids from Hibiscus sabdariffa L. with PPARδ/γ Dual Agonist Action: In Vivo, In Vitro and In Silico Studies.
    Giacoman-Martínez A; Alarcón-Aguilar FJ; Zamilpa A; Hidalgo-Figueroa S; Navarrete-Vázquez G; García-Macedo R; Román-Ramos R; Almanza-Pérez JC
    Planta Med; 2019 Mar; 85(5):412-423. PubMed ID: 30650453
    [No Abstract]   [Full Text] [Related]  

  • 15. Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases.
    Christiansen E; Watterson KR; Stocker CJ; Sokol E; Jenkins L; Simon K; Grundmann M; Petersen RK; Wargent ET; Hudson BD; Kostenis E; Ejsing CS; Cawthorne MA; Milligan G; Ulven T
    Br J Nutr; 2015 Jun; 113(11):1677-88. PubMed ID: 25916176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold.
    Li Z; Liu C; Yang J; Zhou J; Ye Z; Feng D; Yue N; Tong J; Huang W; Qian H
    Eur J Med Chem; 2019 Oct; 179():608-622. PubMed ID: 31279294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
    Li Z; Pan M; Su X; Dai Y; Fu M; Cai X; Shi W; Huang W; Qian H
    Bioorg Med Chem; 2016 May; 24(9):1981-7. PubMed ID: 27020683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of novel dual PPARα/δ agonists for the treatment of T2DM.
    Ren Q; Deng L; Zhou Z; Wang X; Hu L; Xie R; Li Z
    Bioorg Chem; 2020 Aug; 101():103963. PubMed ID: 32480174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents.
    Zhou Z; Ren Q; Jiao S; Cai Z; Geng X; Deng L; Wang B; Hu L; Zhang L; Yang Y; Li Z
    Eur J Med Chem; 2022 Feb; 229():114061. PubMed ID: 34954593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of phenylsulfonyl acetic acid derivatives with improved efficacy and safety as potent free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
    Li Z; Liu C; Xu X; Qiu Q; Su X; Dai Y; Yang J; Li H; Shi W; Liao C; Pan M; Huang W; Qian H
    Eur J Med Chem; 2017 Sep; 138():458-479. PubMed ID: 28689096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.